Abstract A85: The role of LAP positive immune cells in cancer
| Autor: | Brendan Kenyon, Nathaniel Skillin, Rafael M. Rezende, Andre Pires da Cunha, Lena Walton, Murugaiyan Gopal, Galina Gabriely, Howard L. Weiner |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
education.field_of_study biology business.industry Melanoma medicine.medical_treatment digestive oral and skin physiology Immunology Population Cancer Immunotherapy Dendritic cell equipment and supplies medicine.disease Immune system Cytokine medicine Cancer research biology.protein Antibody education business human activities |
| Zdroj: | Cancer Immunology Research. 8:A85-A85 |
| ISSN: | 2326-6074 2326-6066 |
| Popis: | Immunotherapy that acts by counteracting the suppressive environment established by the tumor became a very promising approach for the treatment of cancer. Regulatory immune cells promote cancer by suppressing antitumor immune responses, but there are few cell surface molecules that can specifically be targeted to neutralize their function. We characterized a regulatory T-cell population that expresses surface latency-associated peptide (LAP). LAP is an adaptor and regulator of TGF-beta, a potent immunosuppressive cytokine. An increase in LAP+ CD4 T cells has been reported in human cancer, including head and neck and colorectal cancer. To study the regulatory role of LAP+ cells in cancer, we developed a murine monoclonal anti-LAP antibody. We found that treatment with anti-LAP antibody reduces tumor growth and increases survival in various cancer models, including colon carcinoma, glioblastoma and melanoma. Anti-LAP antibody is able to block TGF-beta release from cells expressing LAP and also reduces both the number and suppressive abilities of tumor-associated LAP+ regulatory cells. Anti-LAP antibody treatment triggers a profound peripheral immune response by acting on both innate and adaptive arms of the immune system. A synergistic antitumor effect was observed by combining anti-LAP antibody with dendritic cell vaccination. To study different LAP+ immune cells on a single-cell level, we developed a 19-panel flow cytometry approach. Based on the TCGA data analysis, the expression of LAP-associated genes correlates inversely with patient survival in a number of cancers. In summary, LAP+ immune cells contribute to cancer progression, and targeting these cells for cancer treatment represents a promising immunotherapeutic approach against cancer. Citation Format: Galina Gabriely, Andre da Cunha, Rafael Rezende, Nathaniel Skillin, Brendan Kenyon, Lena Walton, Murugaiyan Gopal, Howard Weiner. The role of LAP positive immune cells in cancer [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr A85. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|